Skip to main
  1. Stocks
  2. Ocular Therapeutix
  3. Forecast
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is favored because AXPAXLI has already produced positive Phase 3 wet AMD data, with SOL-1 showing superiority to a single aflibercept injection and the program advancing toward an NDA submission expected in 4Q26 under the 505(b)(2) pathway. The thesis is strengthened by SOL-R design features that should improve the odds of success, including screening out patients with early persistent retinal fluid or variability, while interim safety data in the current quarter and more than 300 patients with at least one year of follow-up support the filing. Financially, the company reported $12.9M in revenue, a $94.8M net loss in 3Q26, and $530.6M in cash at the end of September 2026, with management expecting runway into 2028 to fund clinical, pre-commercial, and launch preparations.

Bears say

Ocular Therapeutix is highly dependent on Axpaxli, a Phase 3 candidate for wet AMD and NPDR, so any clinical setback, unexpected safety issue, or unfavorable FDA review of the NDA package could materially impair its main growth driver. Even with positive Phase 3 SOL-1 data, commercialization still faces meaningful hurdles from restrictive labeling risk, competition from entrenched anti-VEGF products, reimbursement pressure, and the need for physician and payer adoption. Financially, the company has one revenue-generating product, has incurred significant losses since inception, and will likely need substantial additional capital to fund development, commercialization, and further indications, leaving the stock exposed to dilution and high volatility.

Ocular Therapeutix (OCUL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction

Get the latest Ocular Therapeutix (OCUL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ocular Therapeutix (OCUL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction

Get the latest Ocular Therapeutix (OCUL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ocular Therapeutix (OCUL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OCUL stock data and trends